Insmed Surges on $210M Volume as Institutional Buys and Analysts Boost Confidence Despite Insider Sales

On September 9, 2025, Insmed (NASDAQ: INSM) rose 0.35% with a trading volume of $210 million, ranking 494th in market activity. Institutional investors including Ieq Capital LLC and Vident Advisory LLC increased stakes in the biopharmaceutical firm during Q1, with purchases totaling $244,000 and $523,000 respectively. Affinity Asset Advisors and Comerica Bank also significantly expanded holdings, adding 180% and 70% to their positions.

Analysts remain optimistic, with 16 firms assigning a "Buy" rating and target prices ranging from $100 to $145. Recent upgrades from Truist, Goldman Sachs, and UBS raised price objectives to $139–$142, while Leerink Partners and Stifel Nicolaus maintained "Outperform" ratings. The stock carries a "Moderate Buy" consensus and an average target of $134.79. Despite a -25.41 P/E ratio and Q2 earnings shortfall of $0.40 per share, quarterly revenue grew 18.9% year-over-year to $107.42 million.

Insider sales reduced ownership stakes by insiders including COO Roger Adsett and Michael Alexander Smith, with combined sales exceeding $54.5 million in three months. However, institutional purchases and analyst upgrades suggest confidence in Insmed’s long-term trajectory. The stock trades near its 52-week high of $146.84, with a market cap of $30.67 billion and a beta of 0.97.

To run this back-test rigorously I need to pin down a few practical details: 1. Universe—whole U.S. equity universe or S&P 500? 2. Ranking & trade timing—previous day’s volume or same-day close? 3. Weighting—equal-weight or volume/market-cap weighted? With these points confirmed, data retrieval and analysis can proceed from 2022-01-03 to the latest trading date.